Breast cancer subtypes can be characterised by the expression of oestrogen, progesterone and human epidermal growth factor (HER2) receptors on the surface of tumour cells. The identification of these subtypes plays a crucial role in selection of the optimal treatment plan for a patient with breast cancer. The most common subtype of breast cancer is hormone-receptor-positive (HR+), HER2-negative breast cancer accounting for approximately 70% of female breast cancer cases world-wide. HR+/ HER2- breast cancer also carries the best prognosis with a 5-year relative survival rate of approximately 95.1%. Treatments that target hormone receptors in both the early and advanced settings can provide excellent clinical outcomes for patients and are associated with less toxicity than chemotherapy.1, 2
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
